Jacob Sands, MD / Luis Paz-Ares, MD, PhD - Advancing Care in EGFR-Mutated NSCLC: Unveiling New Horizons With ADCs

Please visit answersincme.com/BPB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in colorectal cancer discusses the latest guidelines and evidence for later-line treatment of metastatic colorectal cancer (mCRC), as well as strategies for treatment selection and survivorship care. Upon completion of this activity, participants should be better able to: Review guideline recommendations for the later-line treatment of mCRC; Discuss the clinical impact of approved later-line treatments in patients with mCRC; and Outline personalized strategies to optimize outcomes for patients with mCRC who require later-line treatment.

Please visit answersincme.com/GPV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses bispecific antibodies in the current treatment landscape of relapsed/refractory multiple myeloma. Upon completion of this activity, participants should be better able to: Review the role of bispecific antibodies in the current treatment landscape of relapsed/refractory (R/R) multiple myeloma (MM); Discuss the clinical profiles of approved and late-stage emerging bispecific antibodies in heavily pretreated R/R MM; and Describe strategies to optimize outcomes with bispecific antibodies for the treatment of R/R MM. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/NRR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in the treatment of IgA nephropathy (IgAN) discusses novel therapeutic approaches in the management of IgAN. Upon completion of this activity, participants should be better able to: Outline the unmet needs in patients with IgAN; Discuss the clinical implications of new and emerging targeted therapies in IgAN; and Identify patient-centered strategies for long-term management of IgAN.

Please visit answersincme.com/TSJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses systemic therapy, including biologics, for the management of moderate to severe asthma. Upon completion of this activity, participants should be better able to: Review recommended management strategies for moderate to severe asthma; Explain the rationale for the use of biologics in the treatment of patients with moderate to severe asthma; Identify patients eligible for systemic therapy for the treatment of moderate to severe asthma; and Outline evidence-based, long-term strategies to improve lung function in patients with moderate to severe asthma.

Please visit answersincme.com/XCQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in urology discuss the latest data for treatments of overactive bladder. Upon completion of this activity, participants should be better able to: Review the current treatment landscape of OAB; Discuss the clinical significance of the latest efficacy and safety data for beta-3 adrenergic agonists for the treatment of OAB; and Outline evidence-based, patient-centered strategies to optimally use beta-3 adrenergic agonists for the treatment of patients with OAB.

Please visit answersincme.com/KSU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in otolaryngology discuss the role of biologic therapies in chronic rhinosinusitis with nasal polyps (CRSwNP). Upon completion of this activity, participants should be better able to: Recognize considerations for initiating treatment with a biologic therapy in patients with CRSwNP; Review the clinical implications of the latest efficacy and safety data for novel approved biologics in CRSwNP; and Outline strategies to optimize the use of biologics in patients with CRSwNP over the long term.

Please visit answersincme.com/WJM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in medical oncology discusses strategies for patient-centered management of immune-related adverse events (AEs) in patients receiving immunotherapy for nonmelanoma skin cancer (NMSC). Upon completion of this activity, participants should be better able to: Identify counseling strategies to educate patients and caregivers about AEs related to immunotherapy regimens for melanoma and NMSC; Describe monitoring schedules for short- and long-term immunotherapy-associated AEs; and Outline multidisciplinary management strategies for immunotherapy-associated AEs in dermatologic malignancies. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/SWT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the importance of biomarker testing in solid tumors. Upon completion of this activity, participants should be better able to: Recognize the impact of biomarker testing on patient outcomes across tumor types; Identify optimal strategies for implementing biomarker testing in clinical practice; and Outline patient-centered strategies to optimize outcomes following identification of actionable biomarkers/mutations.

Please visit answersincme.com/860/94256783-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss the rationale and strategies for integrating perioperative immunotherapeutic approaches to resectable NSCLC care plans, and a patient joins the conversation to share her story. Upon completion of this activity, participants should be better able to: Explain the rationale for perioperative immunotherapeutic approaches in the treatment landscape of resectable non-small cell lung cancer (rNSCLC); and Identify when perioperative immunotherapeutic approaches should be considered for patients with rNSCLC.

Please visit answersincme.com/VNG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in reproductive health discusses the rationale for human papillomavirus (HPV) vaccination in appropriate adults, its clinical impact, and strategies to incorporate HPV vaccination into prevention plans. Upon completion of this activity, participants should be better able to: Recognize the rationale for HPV vaccination in appropriate adults ages 27-45 years old; Review the clinical impact of HPV vaccination in appropriate adults ages 27-45 years old; and Outline patient-centered strategies to appropriately incorporate HPV vaccination into prevention plans for eligible adults ages 27-45 years old.